Study Question: Are modifications in the embryo culture protocol needed to perform non-invasive preimplantation genetic testing for aneuploidies (niPGT-A) affecting clinical reproductive outcomes, including blastocyst development and pregnancy outcomes?
Summary Answer: The implementation of an embryo culture protocol to accommodate niPGT-A has no impact on blastocyst viability or pregnancy outcomes.
What Is Known Already: The recent identification of embryo cell-free (cf) DNA in spent blastocyst media has created the possibility of simplifying PGT-A. Concerns, however, have arisen at two levels.
Fertil Steril
April 2013
Objective: To evaluate the presence of merocyanine 540 (M540) bodies and their impact on the measurement of apoptotic biomarkers in human spermatozoa.
Design: Case-control, prospective study.
Setting: Academic centers.
Objective: To compare the inflammatory response preserved ex vivo by decidual cells isolated from women who experienced preterm labor with and without subclinical intrauterine infection.
Methods: Fetal membranes were obtained after cesarean section from 35 women who delivered before 37 weeks of gestation following spontaneous preterm labor, with no clinical evidence of intrauterine infection. Decidua was microbiologically tested and cultured.
Objective: To evaluate the impact of age on the expression of apoptotic biomarkers in human spermatozoa.
Design: Cross sectional, prospective study.
Setting: Academic centers.
The objective of this review was to examine the role of the various spermatozoal components suspected of actively participating in early human development. The contributions of the fertilizing spermatozoon to the oocyte include, as a minimum, the delivery of the DNA/chromatin, a putative oocyte-activating factor (OAF), and a centriole. Recent data indicate that spermatozoa may also provide the zygote with a unique suite of paternal mRNAs; some transcripts might be crucial for early and late embryonic development and deficient delivery, or aberrant transcription might contribute to abnormal development and arrest.
View Article and Find Full Text PDFObjective: To study the efficacy of the aromatase inhibitor letrozole as adjuvant to recombinant FSH (rFSH) in controlled ovarian hyperstimulation (COH).
Design: Prospective, randomized, and blinded clinical study.
Setting: Academic tertiary institute.
Objective: To examine whether a relationship exists between loss of mitochondrial transmembrane potential and plasma membrane translocation of phosphatidylserine (PS) in subpopulations of human spermatozoa of men consulting for infertility.
Setting: A tertiary institutional research center.
Design: Prospective observational study.
Objective: To critically discuss the current protocols for the management of controlled ovarian hyperstimulation in assisted reproduction technology.
Design: Review of the literature and presentation of our experience.
Main Outcome Measure(s): Ovarian response (peak serum estrogen levels, number of oocytes retrieved, quality of oocytes and embryos) and pregnancy outcome (clinical, delivery, and multiple pregnancy rates).
Objective: To evaluate sperm recovery and total sperm motility in three different sperm preparation techniques (density gradient, simple washing and swim-up).
Patients And Methods: A total of 290 subjects were randomly evaluated from November 2001 to March 2003. The density gradient method required Isolate (upper and lower layers).
J Am Assoc Gynecol Laparosc
August 2004
Octylcyanoacrylate tissue adhesive glue is a wound closure device recently approved by the U.S. Food and Drug Administration.
View Article and Find Full Text PDFObjective: To evaluate the impact of the enzymatic inhibition complex of metaloproteinases [TIMP(MMP-3 stromelisine-1)] in follicle/genesis processes and their ovule/embryonic subsequent development in stimulated cycles.
Type Of Study: Prospective longitudinal in research center.
Materials And Methods: A total of 20 patients were evaluated in vitro fertilization cycles measuring matrix metaloproteinases concentrations in days 3 and 12 of ovarian stimulation, as well as in the follicular liquid at the moment of ovarian retrieval.